#Coolterm 104 framing error skin

Use the Cygwin terminal to navigate to the example folder (e.g. The example shows basically basic input-output operation (push-button input, LED output), and also basic Rime broadcast communication ( Rime is the light-weight wireless protocol used in Contiki).This blog post describes step-by-step guide to compile, run, and analyze the cc2538dk example of Contiki 2.7.Ĭompiling the cc2538dk example is really similar to the hello-world example which is described in my previous post. Looking into the list of examples, the Contiki 2.7 is also delivered with a CC2538DK specific example which is located under contiki-2.7/examples/cc2538dk. When asked when he thought his drug for blood cancer could be in the clinic, Ross noted that there was still a ways to go, responding, “optimistically, within two years.In my previous post, I have shown the step-by-step guide to compile the basic hello-world demo of Contiki 2.7 for CC2538DK on Windows. More similar to Ross’ approach, PureTech has a platform searching for an oral prodrug that can evade the liver by going through the lymph nodes. The biotech has a Phase I/II study ongoing for an amph-ligand cancer vaccine for KRAS-mutated cancers.

#Coolterm 104 framing error skin

In a paper published earlier this week in PNAS, researchers from Tufts University describe an mRNA cancer vaccine targeted to the lymph nodes that boosts T cell response in skin cancer.Īnd Elicio Therapeutics, founded based on work done in Darrell Irvine’s lab at MIT, is working on “amph-ligands,” in which some drug or protein is bound to a lymph node-targeting lipid. Other biotechs and researchers are also toying with the concept of a lymphatically absorbed cancer drug, albeit with different approaches. Ross has spun his lab’s finding off into a new biotech, named Lympharma, where he is both co-founder and CEO. They are currently testing potential hypothesis, Ross said, noting that it’s a process that takes time. The catch, however, is that Ross and his team are still figuring out how exactly their drug works. When the researchers put the drug into mice with myelofibrosis, a form of blood cancer where scar tissue builds up in the bone marrow, they saw that all the mice treated with their drug survived to 28 days after treatment - the planned cutoff for the study - while control group mice had progressive disease, “reaching humane endpoints” before 21 days. “The drug is filling up this big reservoir - it’s being sequestered away from the entire body by the absorption, and then slowly draining over a day into a neck vein.”Īnd that slow drip from the lymphatic system means that the drug doesn’t cause an initial spike like traditional oral drugs.

Instead, the lymph nodes were “sort of like a gas can that you fill up in your car,” Ross said. The broken-down parts of those drugs can contribute to liver damage, but their drug avoided that by going through the lymph system, according to Ross. Most oral drugs are absorbed through the blood, meaning they first pass through the liver, where some drugs are metabolized. “To my mind, it’s the world’s first kinase inhibitor that’s lymphatically absorbed,” he said. “It was quite astonishing, actually.” So we retooled the group, retooled the lab … and we found it, in fact, was lymphatically absorbed,” Ross said. “After talking to colleagues, we thought perhaps this is a lymphatically absorbed drug. But when it came to this drug, a PI3K and MAPK inhibitor dubbed LP-182, they noticed it was behaving differently and that it was being absorbed at a different rate. Over those six years, Ross’ lab has been looking at unconventional structures for and publishing about multifunctional inhibitors.